
  
    
      
        Background_NNP
        
          Selection_NN of_IN Candidate_NNP Genes_NNP for_IN ISGS_NNP
          The_DT candidate_NN genes_NNS for_IN this_DT study_NN include_VBP the_DT gene_NN
          encoding_VBG β-fibrinogen_JJ and_CC the_DT genes_NNS encoding_VBG platelet_NN
          glycoprotein_NN (_( GP_NNP )_) receptors_NNS Ia_NNP /_NN IIa_NNP ,_, Ib_NNP /_NN IX_CD /_NN V_NNP ,_, and_CC
          IIb_NNP /_NN IIIa_NNP ._. In_IN selecting_VBG candidate_NN genes_NNS for_IN an_DT association_NN
          study_NN ,_, effects_NNS of_IN polymorphisms_NNS on_IN structure_NN ,_, function_NN ,_,
          or_CC expression_NN of_IN a_DT gene_NN product_NN should_MD be_VB considered_VBN ._.
          Failure_NN to_TO consider_VB the_DT underlying_VBG pathophysiologic_JJ
          mechanism_NN when_WRB searching_VBG for_IN polymorphisms_NNS associated_VBN
          with_IN stroke_NN might_MD result_VB in_IN mistaking_VBG association_NN for_IN
          causation_NN [_NN 2_CD ]_NN ._. We_PRP studied_VBD genes_NNS related_VBN to_TO thrombosis_NNS
          because_IN the_DT importance_NN of_IN thrombosis_NNS in_IN acute_JJ ischemic_JJ
          stroke_NN has_VBZ been_VBN established_VBN conclusively_RB in_IN numerous_JJ
          clinical_JJ trials_NNS of_IN treatment_NN and_CC prevention_NN [_NN 3_CD 4_CD 5_CD 6_CD 7_CD 8_CD
          ]_NN ._. We_PRP focused_VBD on_IN genetic_JJ variations_NNS in_IN the_DT fibrinogen_NN
          gene_NN cluster_NN because_IN of_IN the_DT efficacy_NN of_IN fibrinolytic_JJ
          agents_NNS in_IN the_DT acute_JJ treatment_NN of_IN ischemic_JJ stroke_NN ._. In_IN
          addition_NN ,_, we_PRP studied_VBD genes_NNS encoding_VBG for_IN platelet_NN
          receptors_NNS because_IN of_IN the_DT efficacy_NN of_IN platelet_NN
          anti-aggregant_JJ therapy_NN in_IN preventing_VBG first-time_JJ and_CC
          recurrent_JJ ischemic_JJ strokes_NNS ._.
          To_TO restrict_VB the_DT choice_NN of_IN polymorphisms_NNS worthy_JJ of_IN
          further_RBR study_NN ,_, we_PRP constructed_VBN an_DT evidence_NN table_NN from_IN
          reports_NNS appearing_VBG in_IN MEDLINE-indexed_NNP English_NNP language_NN
          journals_NNS describing_VBG cross-sectional_JJ or_CC longitudinal_NN
          studies_NNS of_IN at_IN least_JJS one_CD thrombosis_NNS gene_NN polymorphism_NN in_IN
          at_IN least_JJS 100_CD patients_NNS with_IN stroke_NN ._. Results_NNS were_VBD
          classified_VBN as_IN positive_JJ or_CC negative_NN according_VBG to_TO whether_IN a_DT
          significant_JJ association_NN (_( 
          P_NN <_NN 0_CD ._. 05_CD )_) was_VBD found_VBN between_IN
          stroke_NN (_( or_CC carotid_NN atherosclerosis_NNS )_) and_CC a_DT polymorphism_NN ._.
          Because_IN it_PRP is_VBZ biologically_RB plausible_JJ that_IN a_DT prothrombotic_JJ
          polymorphism_NN may_MD exert_VB a_DT differential_NN effect_NN across_IN
          different_JJ ages_NNS ,_, sexes_NNS ,_, and_CC ethnic_JJ groups_NNS ,_, we_PRP classified_VBD
          studies_NNS as_IN having_VBG positive_JJ results_NNS even_RB if_IN they_PRP had_VBD only_RB
          one_CD positive_JJ subgroup_NN ._. We_PRP considered_VBD a_DT polymorphism_NN
          worthy_JJ of_IN further_RBR study_NN if_IN it_PRP was_VBD not_RB already_RB a_DT clearly_RB
          established_VBN stroke_NN risk_NN factor_NN and_CC if_IN at_IN least_JJS one_CD
          association_NN study_NN was_VBD positive_JJ ._.
          Regarding_VBG a_DT possible_JJ relationship_NN to_TO stroke_NN risk_NN ,_, most_JJS
          studies_NNS of_IN hemostasis_NNS genes_NNS have_VBP been_VBN inconclusive_JJ at_IN
          best_JJS and_CC unconvincing_JJ at_IN worst_JJS ._. On_IN the_DT basis_NN of_IN the_DT
          evidence_NN ,_, we_PRP concluded_VBD that_IN the_DT polymorphisms_NNS of_IN factor_NN
          VII_NNP R_NNP 353_CD Q_NNP ,_, factor_NN XIII_NNP Val_NNP 34_CD Leu_NNP ,_, plasminogen_NN activator_NN
          inhibitor-_NN 1_CD 4_CD G_NNP /_NN 5_CD G_NNP ,_, and_CC prothrombin_NN G_NNP 20210_CD A_DT were_VBD not_RB
          worthy_JJ of_IN further_JJ investigation_NN because_IN large_JJ studies_NNS had_VBD
          consistently_RB yielded_VBN negative_JJ results_NNS (_( Table_NNP 1_LS )_) ._. For_IN
          similar_JJ reasons_NNS ,_, we_PRP decided_VBD not_RB to_TO study_VB factor_NN V_NNP R_NNP 506_CD Q_NNP
          (_( G_NNP 1691_CD A_DT ;_: i_NNP ._. e_SYM ._. ,_, the_DT factor_NN V_NNP Leiden_NNP mutation_NN )_) ,_, despite_IN its_PRP$
          apparent_JJ association_NN with_IN cerebral_JJ vein_NN thrombosis_NNS [_NN 9_CD ]_NN
          ._. Although_IN unknown_JJ point_NN mutations_NNS in_IN the_DT coding_VBG regions_NNS
          of_IN these_DT genes_NNS may_MD relate_VB to_TO stroke_NN and_CC relevant_JJ
          variations_NNS in_IN gene_NN expression_NN elements_NNS may_MD exist_VB ,_, we_PRP
          decided_VBD to_TO focus_VB on_IN more_RBR immediately_RB high-yield_JJ candidate_NN
          genes_NNS ._.
          The_DT results_NNS of_IN three_CD large_JJ European_JJ studies_NNS listed_VBN in_IN
          Table_NNP 1_CD led_VBN us_PRP to_TO conclude_VB that_IN the_DT β-fibrinogen_JJ gene_NN
          might_MD be_VB a_DT promising_JJ candidate_NN ._. Fibrinogen_NNP is_VBZ a_DT
          340_CD ,_, 000_CD -_: Da_NNP GP_NNP consisting_VBG of_IN three_CD polypeptide_NN chains_NNS :_: α_NN ,_,
          β_NN ,_, and_CC γ_NN ._. The_DT genes_NNS that_WDT encode_NN these_DT polypeptides_NNS reside_VB
          on_IN chromosome_NN 4_CD q_NN in_IN a_DT cluster_NN ._. In_IN a_DT study_NN of_IN the_DT
          β-fibrinogen_JJ G_NNP 455_CD A_DT polymorphism_NN ,_, Kessler_NNP et_CC al_NN ._. [_NN 10_CD ]_NN
          did_VBD not_RB find_VB an_DT overall_JJ association_NN between_IN genotype_NN and_CC
          stroke_NN ,_, but_CC heterozygosity_NN for_IN the_DT A_DT allele_NN was_VBD
          associated_VBN with_IN large-vessel_JJ ischemic_JJ stroke_NN (_( 
          P_NN =_SYM 0_CD ._. 045_CD )_) ._. Schmidt_NNP et_CC al_NN ._. [_NN 11_CD ]_NN
          observed_VBD an_DT association_NN between_IN carotid_NN atherosclerosis_NNS
          and_CC the_DT C_NNP 148_CD T_NN polymorphism_NN in_IN a_DT population-based_JJ
          cross-sectional_JJ study_NN of_IN persons_NNS with_IN normal_JJ neurologic_JJ
          status_NN ._. Carotid_NNP atherosclerosis_NNS was_VBD seen_VBN in_IN 53_CD ._. 6_CD %_NN of_IN
          persons_NNS with_IN the_DT C_NNP /_NN C_NNP genotype_NN ,_, 54_CD ._. 1_LS %_NN of_IN those_DT with_IN the_DT
          C_NNP /_NN T_NN genotype_NN ,_, and_CC 88_CD %_NN of_IN those_DT with_IN the_DT T_NN /_NN T_NN genotype_NN (_( 
          P_NN =_SYM 0_CD ._. 003_CD )_) ._. Abnormal_NNP results_NNS on_IN
          carotid_NN ultrasonography_NN were_VBD significantly_RB more_RBR common_JJ in_IN
          the_DT T_NN /_NN T_NN genotype_NN group_NN (_( OR_NNP ,_, 6_CD ._. 29_CD ;_: 95_CD %_NN CI_NNP ,_, 1_CD ._. 91_CD to_TO 20_CD ._. 71_CD )_) ._.
          Data_NNS from_IN the_DT study_NN by_IN Carter_NNP et_CC al_NN ._. [_NN 12_CD ]_NN on_IN the_DT G_NNP 448_CD A_DT
          polymorphism_NN of_IN the_DT β-fibrinogen_JJ gene_NN suggested_VBD that_IN
          mechanisms_NNS linking_VBG fibrinogen_NN and_CC the_DT development_NN of_IN
          cerebrovascular_NN disease_NN may_MD be_VB different_JJ in_IN men_NNS and_CC
          women_NNS ._.
          Several_JJ studies_NNS listed_VBN in_IN Table_NNP 1_CD suggested_VBD that_IN
          polymorphisms_NNS of_IN genes_NNS controlling_VBG the_DT three_CD platelet_NN
          glycoprotein_NN receptors_NNS Ia_NNP /_NN IIa_NNP ,_, Ib_NNP /_NN IX_CD /_NN V_NNP ,_, and_CC IIb_NNP /_NN IIIa_NNP ,_,
          which_WDT play_VBP a_DT role_NN in_IN adhesion_NN ,_, might_MD also_RB be_VB promising_JJ
          candidate_NN risk_NN factors_NNS for_IN stroke_NN ._. GP_NNP Ia_NNP /_NN IIa_NNP (_( integrin_NN α_NN 
          2_CD β_NN 
          1_LS )_) is_VBZ involved_VBN in_IN collagen-induced_JJ
          platelet_NN aggregation_NN ._. It_PRP does_VBZ not_RB bind_NN collagen_NN monomers_NNS ,_,
          but_CC it_PRP does_VBZ bind_NN collagen_NN fibrils_NNS and_CC immobilized_JJ
          collagen_NN ._. Binding_NNP of_IN GPIa_NNP /_NN IIa_NNP to_TO collagen_NN induces_VBZ a_DT
          conformational_NN change_NN in_IN receptor_NN structure_NN that_WDT enhances_VBZ
          affinity_NN ._. Thus_RB ,_, one_CD platelet_NN GP_NNP of_IN interest_NN is_VBZ GPIa_NNP ._.
          Carlsson_NNP et_CC al_NN ._. [_NN 13_CD ]_NN compared_VBD the_DT GPIa_NNP (_( α_NN 
          2_LS )_) C_NNP 807_CD T_NN genotype_NN distribution_NN in_IN
          patients_NNS with_IN ischemic_JJ stroke_NN or_CC transient_JJ ischemic_JJ
          attacks_NNS with_IN that_DT in_IN hospitalized_VBN patients_NNS without_IN
          cerebrovascular_NN disease_NN and_CC in_IN healthy_JJ blood_NN donors_NNS ._. An_DT
          association_NN between_IN the_DT polymorphism_NN and_CC stroke_NN was_VBD not_RB
          seen_VBN overall_JJ ._. However_RB ,_, there_EX was_VBD an_DT overrepresentation_NN of_IN
          the_DT C_NNP 807_CD T_NN polymorphism_NN in_IN patients_NNS with_IN stroke_NN age_NN 50_CD
          years_NNS or_CC younger_JJR (_( 
          n_NN =_SYM 45_CD )_) versus_CC age-matched_JJ controls_NNS
          (_( OR_NNP ,_, 3_CD ._. 02_CD ;_: 95_CD %_NN CI_NNP ,_, 1_CD ._. 20_CD to_TO 7_CD ._. 61_CD )_) ._. No_DT such_JJ
          overrepresentation_NN was_VBD detected_VBN in_IN older_JJR patients_NNS ._.
          The_DT second_JJ platelet_NN GP_NNP of_IN interest_NN is_VBZ GPIbα_NNP ,_, a_DT
          transmembranous_JJ platelet_NN GP_NNP (_( molecular_JJ weight_NN ,_, 143_CD ,_, 000_CD )_)
          that_IN forms_NNS noncovalent_NN complexes_NNS with_IN GPIbβ_NNP ,_, GPIX_NNP ,_, and_CC
          GPV_NNP to_TO form_VB the_DT GPIb_NNP /_NN IX_CD /_NN V_NNP receptor_NN ,_, which_WDT is_VBZ involved_VBN in_IN
          shear_NN stress-induced_JJ platelet_NN activation_NN by_IN binding_JJ to_TO
          von_NNP Willebrand_NNP factor_NN (_( vWF_NN )_) ._. This_DT receptor_NN may_MD be_VB
          particularly_RB relevant_JJ in_IN large-vessel_JJ atherosclerotic_JJ
          ischemic_JJ stroke_NN because_IN high_JJ shear_NN stresses_VBZ like_IN those_DT
          seen_VBN in_IN atherosclerotic_JJ arteries_NNS increase_VBP ligand-receptor_JJ
          affinity_NN ._. The_DT receptor_NN may_MD also_RB have_VB a_DT role_NN in_IN so-called_JJ
          aspirin_NN failure_NN ,_, in_IN which_WDT patients_NNS suffer_VBP stroke_NN despite_IN
          taking_VBG daily_JJ aspirin_NN prophylaxis_NNS ._. Cyclooxygenase_NNP
          inhibition_NN by_IN aspirin_NN has_VBZ little_JJ effect_NN on_IN initial_JJ
          aggregation_NN in_IN response_NN to_TO shear_NN forces_NNS ._. One_CD GPIbα_NNP
          polymorphism_NN is_VBZ referred_VBN to_TO as_IN "_'' VNTR_NNP "_'' because_IN it_PRP consists_VBZ
          of_IN a_DT variable_JJ number_NN of_IN tandem_JJ repeats_NNS of_IN 39_CD base_NN pairs_NNS ,_,
          each_DT repeat_NN leading_VBG to_TO a_DT 13_CD -_: amino_JJ acid_NN addition_NN that_WDT
          pushes_VBZ a_DT vWF-binding_JJ domain_NN further_JJ away_RB from_IN the_DT
          platelet_NN membrane_NN surface_NN ._. Another_DT is_VBZ human_JJ platelet_NN
          antigen-_NN 2_CD (_( HPA-_NNP 2_LS )_) ,_, a_DT mutation_NN that_IN codes_NNS for_IN either_DT a_DT thr_NN
          (_( HPA-_NNP 2_CD a_DT )_) or_CC met_VBD (_( HPA-_NNP 2_CD b_SYM )_) at_IN position_NN 145_CD ._. The_DT HPA-_NNP 2_CD site_NN
          resides_VBZ next_JJ to_TO the_DT vWF_NN and_CC high-affinity_JJ thrombin_NN
          binding_JJ sites_NNS ._.
          In_IN a_DT case-control_JJ study_NN of_IN these_DT polymorphisms_NNS ,_,
          Gonzalez-_NNP Conejero_NNP et_CC al_NN ._. [_NN 14_CD ]_NN found_VBD that_DT
          cerebrovascular_NN disease_NN was_VBD associated_VBN with_IN both_DT the_DT C_NNP /_NN B_NNP
          genotype_NN of_IN the_DT VNTR_NNP polymorphism_NN (_( OR_NNP ,_, 2_CD ._. 83_CD ;_: 95_CD %_NN CI_NNP ,_, 1_CD ._. 16_CD
          to_TO 7_CD ._. 07_CD ;_: 
          P_NN =_SYM 0_CD ._. 0114_CD )_) and_CC the_DT β_NN allele_NN of_IN the_DT
          HPA-_NNP 2_CD polymorphism_NN ._. Of_IN the_DT 104_CD patients_NNS with_IN
          cerebrovascular_NN disease_NN ,_, 22_CD ._. 11_CD %_NN carried_VBD at_IN least_JJS one_CD β_NN
          allele_NN compared_VBN with_IN 10_CD ._. 58_CD %_NN of_IN controls_NNS (_( OR_NNP ,_, 2_CD ._. 40_CD ;_: 95_CD %_NN
          CI_NNP ,_, 1_CD ._. 04_CD to_TO 5_CD ._. 63_CD ;_: 
          P_NN =_SYM 0_CD ._. 0244_CD )_) ._. Neither_DT polymorphism_NN
          showed_VBD significant_JJ differences_NNS related_VBN to_TO age_NN ,_, sex_NN ,_, or_CC
          type_NN of_IN cerebrovascular_NN disease_NN ._. Both_DT polymorphisms_NNS also_RB
          correlated_JJ with_IN coronary_JJ artery_NN disease_NN ,_, but_CC neither_DT
          correlated_JJ with_IN deep_JJ vein_NN thrombosis_NNS ._. This_DT is_VBZ the_DT
          converse_NN of_IN what_WP Ridker_NNP et_CC al_NN ._. [_NN 15_CD ]_NN and_CC others_NNS found_VBD
          for_IN factor_NN V_NNP Leiden_NNP ._. Taken_VBN together_RB ,_, the_DT studies_NNS suggest_VBP
          that_IN polymorphisms_NNS predisposing_VBG to_TO arterial_NN thrombosis_NNS
          may_MD differ_VB from_IN polymorphisms_NNS predisposing_VBG to_TO deep_JJ vein_NN
          thrombosis_NNS ._. This_DT hypothesis_NNS supports_VBZ the_DT rationale_NN for_IN a_DT
          hemostasis_NNS candidate-gene_JJ association_NN study_NN such_JJ as_IN ISGS_NNP ,_,
          which_WDT investigates_VBZ ischemic_JJ stroke_NN specifically_RB and_CC does_VBZ
          not_RB regard_VB all_DT acute_JJ thrombotic_JJ events_NNS ,_, whether_IN arterial_NN
          or_CC venous_JJ ,_, as_IN a_DT single_JJ clinical_JJ entity_NN ._.
          The_DT third_JJ candidate_NN platelet_NN GP_NNP gene_NN controls_NNS
          GPIIb_NNP /_NN IIIa_NNP (_( integrin_NN α_NN 
          IIb_NNP β_NN 
          3_LS )_) ,_, a_DT transmembranous_JJ heterodimer_NN
          with_IN several_JJ ligands_NNS ,_, including_VBG fibrinogen_NN ,_, fibrin_NN ,_,
          fibronectin_NN ,_, and_CC vWF_NN ._. Many_JJ receptors_NNS are_VBP involved_VBN in_IN
          platelet_NN adhesion_NN and_CC many_JJ agonists_NNS stimulate_VB platelet_NN
          aggregation_NN ,_, but_CC platelet_NN aggregation_NN requires_VBZ
          GPIIb_NNP /_NN IIIa_NNP ._. When_WRB platelets_NNS aggregate_JJ ,_, GPIIb_NNP /_NN IIIa_NNP binds_NNS to_TO
          fibrinogen_NN and_CC vWF_NN ._. Binding_NNP to_TO vWF_NN gains_NNS importance_NN under_IN
          conditions_NNS of_IN high_JJ shear_NN stress_NN ._. Carter_NNP et_CC al_NN ._. [_NN 16_CD ]_NN
          found_VBD no_DT overall_JJ association_NN between_IN the_DT P_NN 1_CD A_DT 2_CD
          polymorphism_NN of_IN the_DT GPIIb_NNP /_NN IIIa_NNP gene_NN and_CC cerebral_JJ
          infarction_NN confirmed_VBN by_IN computed_JJ tomography_NN (_( CT_NNP )_) ._.
          However_RB ,_, a_DT subgroup_NN analysis_NN showed_VBD significant_JJ genotype_NN
          distribution_NN differences_NNS in_IN nonsmokers_NNS ._. The_DT risk_NN of_IN
          stroke_NN was_VBD greater_JJR in_IN nonsmokers_NNS heterozygous_JJ for_IN the_DT
          P_NN 1_CD A_DT 2_CD allele_NN than_IN in_IN those_DT homozygous_JJ for_IN P_NN 1_CD A_DT 2_CD (_( OR_NNP ,_, 2_CD ._. 37_CD ;_:
          95_CD %_NN CI_NNP ,_, 1_CD ._. 19_CD to_TO 4_CD ._. 74_CD ;_: 
          P_NN =_SYM 0_CD ._. 01_CD )_) ._. Information_NNP on_IN young_JJ
          stroke_NN patients_NNS was_VBD limited_JJ (_( 
          n_NN =_SYM 37_CD )_) ,_, but_CC in_IN a_DT logistic_JJ
          regression_NN model_NN that_WDT included_JJ P_NN 1_CD A_DT genotype_NN status_NN ,_,
          smoking_NN ,_, hypertension_NN ,_, and_CC diabetes_NN ,_, the_DT OR_NNP for_IN stroke_NN in_IN
          those_DT possessing_VBG the_DT A_DT 2_CD allele_NN was_VBD 1_CD ._. 68_CD (_( 95_CD %_NN CI_NNP ,_, 1_CD ._. 00_CD to_TO
          2_CD ._. 82_CD ;_: 
          P_NN =_SYM 0_CD ._. 05_CD )_) ._. This_DT study_NN highlights_VBZ
          the_DT need_NN for_IN further_JJ studies_NNS of_IN the_DT interaction_NN between_IN
          genes_NNS and_CC environmental_JJ factors_NNS ,_, in_IN this_DT case_NN smoking_NN ,_, in_IN
          attempts_NNS to_TO elucidate_NN inherited_VBD stroke_NN risk_NN ._.
        
        
          Aims_VBZ
          The_DT primary_JJ aim_NN of_IN ISGS_NNP is_VBZ to_TO test_VB the_DT association_NN
          between_IN ischemic_JJ stroke_NN and_CC the_DT following_VBG putative_JJ risk_NN
          factor_NN polymorphisms_NNS :_: β-fibrinogen_JJ C_NNP 148_CD T_NN ,_, G_NNP 448_CD A_DT ,_, and_CC
          G_NNP 455_CD A_DT ;_: GPIa_NNP C_NNP 807_CD T_NN ;_: GPIbα_NNP HPA-_NNP 2_CD and_CC VNTR_NNP ;_: and_CC GPIIb_NNP /_NN IIIa_NNP
          P_NN 1_CD A_DT ._. Exploratory_NNP aims_NNS are_VBP to_TO investigate_VB whether_IN any_DT
          association_NN found_VBD between_IN ischemic_JJ stroke_NN and_CC the_DT panel_NN
          of_IN tested_VBN polymorphisms_NNS is_VBZ contingent_JJ on_IN sex_NN ,_, age_NN ,_, ethnic_JJ
          origin_NN ,_, smoking_NN status_NN ,_, or_CC stroke_NN subtype_NN and_CC to_TO
          investigate_VB whether_IN hemostatic_JJ gene_NN sequence_NN variations_NNS
          are_VBP associated_VBN with_IN 90_CD -_: day_NN functional_JJ outcome_NN after_IN acute_JJ
          ischemic_JJ stroke_NN ._.
        
      
      
        Methods_NNP
        
          Design_NNP and_CC Overview_NNP
          The_DT ISGS_NNP is_VBZ a_DT prospective_JJ multicenter_NN study_NN using_VBG a_DT
          case-control_JJ design_NN (_( Fig_NNP ._. 1_LS )_) ._. Patients_NNS and_CC control_NN
          subjects_NNS are_VBP screened_VBD at_IN one_CD of_IN five_CD clinical_JJ centers_NNS
          (_( Appendix_NNP 1_CD -_: Additional_JJ file_NN :_: 1_LS )_) ,_, stroke_NN status_NN is_VBZ
          verified_VBN ,_, the_DT index_NN stroke_NN for_IN each_DT patient_NN is_VBZ subtyped_JJ ,_,
          and_CC baseline_NN clinical_JJ and_CC demographic_JJ data_NNS are_VBP collected_VBN ._.
          Blood_NNP samples_NNS are_VBP collected_VBN from_IN all_DT enrolled_VBN patients_NNS
          and_CC control_NN subjects_NNS by_IN means_NNS of_IN a_DT one-time_JJ venipuncture_NN ._.
          The_DT samples_NNS are_VBP shipped_VBN to_TO a_DT central_JJ DNA_NNP bank_NN for_IN
          processing_NN and_CC storage_NN ,_, and_CC the_DT processed_VBN DNA_NNP samples_NNS are_VBP
          sent_VBN to_TO a_DT central_JJ genetics_NNS laboratory_NN for_IN genotyping_VBG ._. The_DT
          genotype_NN data_NN are_VBP then_RB merged_VBN with_IN the_DT clinical_JJ ,_, stroke_NN ,_,
          and_CC follow-up_JJ data_NNS and_CC analyzed_VBD to_TO ascertain_VB potential_JJ
          associations_NNS between_IN stroke_NN risk_NN and_CC genes_NNS for_IN
          β-fibrinogen_JJ and_CC platelet_NN GPIa_NNP ,_, GPIbα_NNP ,_, or_CC GPIIb_NNP /_NN III_NNP ._.
          Additional_JJ file_NN 1_CD
          
          
          Click_NNP here_RB for_IN file_NN
        
        
          Study_NNP Population_NNP
          
            Patients_NNS With_IN Stroke_NNP (_( Cases_NNS )_)
            Each_DT patient_NN with_IN suspected_VBN stroke_NN admitted_VBN to_TO a_DT
            participating_VBG center_NN is_VBZ evaluated_VBN by_IN a_DT study_NN
            neurologist_NN according_VBG to_TO current_JJ standards_NNS for_IN care_NN [_NN
            17_CD 18_CD ]_NN ._. The_DT evaluation_NN includes_VBZ patient_NN history_NN ,_,
            physical_JJ examination_NN ,_, CT_NNP or_CC magnetic_JJ resonance_NN imaging_NN
            (_( MR_NNP )_) of_IN the_DT head_NN ,_, and_CC laboratory_NN testing_NN ._. Where_WRB
            clinically_RB indicated_VBD ,_, the_DT evaluation_NN may_MD also_RB include_VB
            carotid_NN ultrasonography_NN ;_: MR_NNP ,_, CT_NNP ,_, or_CC digital_JJ subtraction_NN
            angiography_NN ;_: transthoracic_JJ or_CC transesophageal_NN
            echocardiography_NN ;_: resting_VBG and_CC ambulatory_JJ
            electrocardiography_NN ;_: intracranial_NN arterial_NN imaging_NN ;_: and_CC
            additional_JJ blood_NN testing_NN ._.
            Adult_NNP men_NNS and_CC women_NNS who_WP meet_VBP the_DT following_VBG criteria_NNS
            are_VBP entered_VBN into_IN the_DT study_NN :_: 1_LS )_) diagnosis_NN of_IN first-ever_JJ
            ischemic_JJ stroke_NN confirmed_VBN by_IN the_DT study_NN neurologist_NN on_IN
            the_DT basis_NN of_IN history_NN ,_, physical_JJ examination_NN ,_, and_CC head_NN
            imaging_NN by_IN CT_NNP or_CC MR_NNP ;_: 2_LS )_) enrollment_NN within_IN 30_CD days_NNS after_IN
            onset_NN of_IN stroke_NN symptoms_NNS ;_: 3_LS )_) attained_VBN 18_CD th_NN birthday_NN by_IN
            the_DT time_NN of_IN enrollment_NN ;_: 4_LS )_) complete_JJ blood_NN cell_NN count_NN ,_,
            casual_JJ or_CC fasting_VBG blood_NN glucose_NN ,_, prothrombin_NN time_NN ,_, and_CC
            activated_VBN partial_JJ thromboplastin_NN time_NN available_JJ ;_: and_CC 5_LS )_)
            written_VBN informed_VBN consent_NN from_IN the_DT patient_NN or_CC
            surrogate_JJ ._.
            Stroke_NNP is_VBZ defined_VBN according_VBG to_TO the_DT World_NNP Health_NNP
            Organization_NNP criteria_NNS [_NN 19_CD ]_NN as_RB rapidly_RB developing_VBG
            signs_NNS of_IN a_DT focal_JJ or_CC global_JJ disturbance_NN of_IN cerebral_JJ
            function_NN with_IN symptoms_NNS lasting_JJ 24_CD hours_NNS or_CC longer_RBR or_CC
            leading_VBG to_TO death_NN ,_, with_IN no_DT apparent_JJ cause_NN other_JJ than_IN
            vascular_NN origin_NN ._. A_DT diagnosis_NN of_IN ischemic_JJ stroke_NN is_VBZ made_VBN
            only_RB if_IN the_DT patient_NN has_VBZ a_DT clinical_JJ diagnosis_NN of_IN stroke_NN
            and_CC if_IN a_DT CT_NNP scan_VB or_CC MR_NNP of_IN the_DT brain_NN done_VBN after_IN onset_NN of_IN
            symptoms_NNS either_DT is_VBZ normal_JJ or_CC shows_VBZ the_DT relevant_JJ
            infarct_NN ._. Patients_NNS with_IN hemorrhagic_JJ transformation_NN of_IN an_DT
            infarct_NN remain_VB eligible_JJ ._.
            Time_NNP of_IN stroke_NN onset_NN is_VBZ defined_VBN as_IN the_DT time_NN when_WRB the_DT
            subject_NN was_VBD last_RB noted_VBD to_TO be_VB at_IN baseline_NN neurologic_JJ
            status_NN ._. If_IN the_DT patient_NN awoke_VBD with_IN stroke_NN symptoms_NNS ,_, the_DT
            time_NN of_IN onset_NN is_VBZ taken_VBN as_IN the_DT last_JJ time_NN the_DT patient_NN was_VBD
            known_VBN to_TO be_VB awake_JJ and_CC without_IN any_DT symptoms_NNS of_IN stroke_NN ._.
            We_PRP restrict_VBP enrollment_NN to_TO within_IN 30_CD days_NNS after_IN onset_NN of_IN
            symptoms_NNS from_IN the_DT first-ever_JJ stroke_NN to_TO avoid_VB potential_JJ
            survival_NN bias_NN [_NN 20_CD 21_CD 22_CD 23_CD ]_NN ._. The_DT date_NN of_IN enrollment_NN
            is_VBZ the_DT date_NN of_IN obtaining_VBG signed_VBN informed_VBN consent_NN ._.
            Exclusion_NNP criteria_NNS parallel_VB those_DT of_IN the_DT Siblings_NNP
            With_IN Ischemic_NNP Stroke_NNP Study_NNP (_( SWISS_NNP )_) [_NN 24_CD ]_NN ._. Patients_NNPS
            who_WP are_VBP already_RB enrolled_VBN in_IN SWISS_NNP are_VBP not_RB eligible_JJ for_IN
            participation_NN in_IN ISGS_NNP ._.
            To_TO be_VB able_JJ to_TO assess_VB the_DT extent_NN to_TO which_WDT enrolled_VBD
            patients_NNS represent_VBP all_DT potential_JJ subjects_NNS ,_, clinical_JJ
            study_NN coordinators_NNS at_IN each_DT site_NN keep_VB logs_NNS of_IN every_DT
            eligible_JJ stroke_NN patient_NN who_WP is_VBZ offered_VBN participation_NN in_IN
            the_DT study_NN ,_, whether_IN or_CC not_RB they_PRP are_VBP enrolled_VBN ._. The_DT logs_NNS
            will_MD contain_VB initials_NNS and_CC date_NN of_IN birth_NN of_IN the_DT eligible_JJ
            stroke_NN patients_NNS ,_, date_NN of_IN screening_NN ,_, sex_NN ,_, and_CC
            race_NN /_NN ethnicity_NN ._.
          
          
            Controls_NNP
            Controls_NNP are_VBP adult_NN men_NNS and_CC women_NNS who_WP have_VBP attained_VBN
            their_PRP$ 18_CD th_NN birthday_NN at_IN the_DT time_NN of_IN enrollment_NN ,_, have_VBP not_RB
            had_VBD a_DT stroke_NN ,_, are_VBP unrelated_JJ by_IN blood_NN to_TO patients_NNS
            enrolled_VBD in_IN the_DT study_NN ,_, and_CC who_WP give_VBP written_VBN informed_VBN
            consent_NN to_TO participate_VB in_IN the_DT study_NN ._. We_PRP confirm_VBP that_IN
            controls_NNS have_VBP not_RB had_VBD a_DT prior_JJ stroke_NN by_IN means_NNS of_IN the_DT
            Questionnaire_NNP for_IN Verifying_NNP Stroke-free_NNP Status_NNP (_( QVSS_NNP )_) ,_,
            a_DT structured_VBN interview_NN that_WDT was_VBD validated_JJ in_IN an_DT adult_NN
            population_NN (_( age_NN ,_, >_NN 60_CD years_NNS )_) using_VBG systematic_JJ review_NN
            of_IN electronic_JJ medical_JJ records_NNS as_IN the_DT benchmark_NN [_NN 25_CD ]_NN ._.
            The_DT QVSS_NNP was_VBD further_JJ validated_JJ in_IN an_DT independent_JJ
            population_NN using_VBG history_NN and_CC physical_JJ examination_NN by_IN a_DT
            study_NN neurologist_NN as_IN the_DT benchmark_NN [_NN 26_CD ]_NN ._.
            Interviewers_NNP administering_VBG the_DT QVSS_NNP may_MD exclude_VB a_DT
            subject_JJ they_PRP judge_VBP to_TO be_VB an_DT unreliable_JJ historian_NN on_IN the_DT
            basis_NN of_IN a_DT global_JJ impression_NN of_IN moderate_JJ or_CC severe_JJ
            impairment_NN of_IN speech_NN ,_, language_NN ,_, hearing_NN ,_, or_CC memory_NN ._.
            Hospitalized_NNP patients_NNS being_VBG treated_VBN for_IN coronary_JJ or_CC
            peripheral_JJ vascular_NN disease_NN are_VBP not_RB eligible_JJ for_IN
            enrollment_NN as_IN controls_NNS ,_, but_CC nonhospitalized_JJ subjects_NNS
            with_IN a_DT history_NN of_IN these_DT conditions_NNS are_VBP eligible_JJ ._.
            Cases_NNS and_CC controls_NNS are_VBP matched_VBN one-to-one_JJ ._. Matching_NNP
            criteria_NNS are_VBP sex_NN and_CC age_NN (_( within_IN 3_CD years_NNS for_IN patients_NNS
            who_WP are_VBP younger_JJR than_IN 30_CD years_NNS and_CC within_IN 5_CD years_NNS for_IN
            patients_NNS who_WP are_VBP 30_CD years_NNS or_CC older_JJR )_) ._. We_PRP recruit_VB
            controls_NNS mainly_RB from_IN among_IN spouses_NNS and_CC unrelated_JJ
            friends_NNS of_IN the_DT patients_NNS ._. Each_DT center_NN has_VBZ a_DT backup_NN plan_NN
            for_IN recruiting_VBG community_NN volunteers_NNS should_MD there_EX be_VB a_DT
            lag_NN in_IN recruitment_NN of_IN properly_RB matched_VBN controls_NNS [_NN 27_CD ]_NN
            ._.
          
        
        
          Data_NNP Collection_NNP
          
            Structured_NNP Interview_NNP
            A_DT structured_VBN interview_NN is_VBZ conducted_VBN by_IN the_DT study_NN
            coordinator_NN with_IN each_DT patient_NN (_( case_NN )_) or_CC surrogate_JJ and_CC
            each_DT control_NN subject_JJ to_TO explain_VB the_DT study_NN ,_, obtain_VB
            informed_VBN consent_NN ,_, and_CC obtain_VB standardized_JJ information_NN
            on_IN baseline_NN medication_NN and_CC demographic_JJ ,_, medical_JJ ,_,
            social_JJ ,_, and_CC behavioral_JJ variables_NNS ._. Information_NNP regarding_VBG
            race_NN and_CC ethnicity_NN is_VBZ recorded_VBN according_VBG to_TO
            self-report_JJ ._. A_DT proband-derived_JJ family_NN history_NN is_VBZ taken_VBN
            for_IN all_DT living_VBG or_CC deceased_JJ full_JJ siblings_NNS ,_, all_DT
            biological_JJ children_NNS ,_, and_CC both_DT biological_JJ parents_NNS [_NN 28_CD ]_NN
            ._. Investigators_NNS do_VBP not_RB independently_RB verify_VB stroke_NN
            status_NN of_IN family_NN members_NNS as_IN part_NN of_IN this_DT protocol_NN ._.
            Self-reported_NNP cerebrovascular_NN histories_NNS are_VBP obtained_VBN
            for_IN all_DT patients_NNS and_CC control_NN subjects_NNS by_IN administering_VBG
            the_DT QVSS_NNP during_IN the_DT baseline_NN interview_NN [_NN 25_CD ]_NN ._.
          
          
            Medical_NNP Records_NNPS
            Study_NN coordinators_NNS review_VBP the_DT medical_JJ records_NNS of_IN the_DT
            initial_JJ evaluation_NN of_IN stroke_NN cases_NNS to_TO complete_VB case_NN
            report_NN forms_NNS for_IN documenting_VBG eligibility_NN and_CC baseline_NN
            data_NNS and_CC to_TO construct_VB the_DT abstracted_JJ medical_JJ record_NN
            used_VBN for_IN stroke_NN subtyping_VBG ._. The_DT following_VBG information_NN is_VBZ
            recorded_VBN on_IN the_DT case_NN report_NN forms_NNS :_: patient_NN history_NN ,_,
            physical_JJ examination_NN ,_, CT_NNP or_CC MR_NNP of_IN the_DT head_NN ,_, white_JJ blood_NN
            cell_NN count_NN ,_, platelet_NN count_NN ,_, and_CC hemoglobin_NN
            concentration_NN ,_, casual_JJ or_CC fasting_VBG blood_NN glucose_NN ,_,
            prothrombin_NN time_NN ,_, and_CC activated_VBN partial_JJ thromboplastin_NN
            time_NN ,_, vital_JJ signs_NNS (_( height_NN ,_, weight_NN ,_, blood_NN pressure_NN ,_, and_CC
            temperature_NN )_) ,_, international_JJ normalized_JJ ratio_NN ,_, lipid_NN
            profile_NN ,_, plasma_NN homocysteine_NN concentration_NN ,_, and_CC size_NN
            and_CC location_NN of_IN the_DT symptomatic_JJ cerebral_JJ infarct_NN as_IN
            seen_VBN on_IN head_NN imaging_NN ._.
            The_DT clinical_JJ coordinator_NN also_RB constructs_NNS the_DT
            abstracted_JJ medical_JJ record_NN used_VBN for_IN subtyping_VBG of_IN the_DT
            index_NN stroke_NN by_IN copying_VBG admission_NN notes_NNS ,_, physician_NN
            progress_NN notes_NNS ,_, discharge_NN summaries_NNS ,_, radiology_NN reports_NNS ,_,
            electrocardiograms_NNS ,_, echocardiography_NN reports_NNS ,_,
            laboratory_NN reports_NNS ,_, and_CC rehabilitation_NN notes_NNS ._.
            Investigators_NNS and_CC coordinators_NNS use_VBP standardized_JJ
            definitions_NNS for_IN major_JJ medical_JJ and_CC surgical_JJ comorbid_NN
            conditions_NNS (_( Appendix_NNP 2_CD -_: see_VB Additional_JJ file_NN :_: 2_LS )_) ._.
            Because_IN blood_NN pressure_NN typically_RB falls_VBZ during_IN the_DT first_JJ
            few_JJ days_NNS after_IN an_DT acute_JJ ischemic_JJ stroke_NN ,_, we_PRP have_VBP
            adopted_VBN a_DT modification_NN of_IN the_DT Northern_NNP Manhattan_NNP Stroke_NNP
            Study_NNP (_( NOMASS_NNP )_) technique_NN [_NN 29_CD ]_NN ,_, in_IN which_WDT we_PRP use_VBP the_DT
            systolic_JJ and_CC diastolic_JJ blood_NN pressure_NN values_NNS measured_VBN
            after_IN admission_NN to_TO the_DT hospital_NN floor_NN (_( or_CC intensive_JJ
            care_NN unit_NN )_) rather_RB than_IN measurements_NNS taken_VBN by_IN the_DT
            emergency_NN medical_JJ service_NN or_CC in_IN the_DT emergency_NN
            department_NN ._. Blood_NNP pressure_NN is_VBZ measured_VBN from_IN the_DT left_NN
            brachial_NN artery_NN (_( if_IN attainable_JJ )_) with_IN a_DT
            sphygmomanometer_NN ,_, with_IN the_DT patient_NN sitting_VBG upright_NN ._. If_IN
            the_DT patient_NN is_VBZ bedbound_NN ,_, the_DT measurement_NN is_VBZ made_VBN with_IN
            the_DT head_NN of_IN the_DT bed_NN elevated_VBD to_TO at_IN least_JJS a_DT 45_CD °_NN
            angle_NN ._.
            Additional_JJ file_NN 2_CD
            
            
            Click_NNP here_RB for_IN file_NN
          
          
            Characterization_NNP of_IN Ischemic_NNP Stroke_NNP
            An_DT on-site_JJ ,_, study-appointed_JJ neurologist_NN confirms_VBZ the_DT
            diagnosis_NN of_IN ischemic_JJ stroke_NN and_CC the_DT time_NN of_IN stroke_NN
            onset_NN by_IN interviewing_VBG patients_NNS or_CC any_DT available_JJ
            observers_NNS present_JJ when_WRB the_DT stroke_NN was_VBD first_RB noticed_JJ [_NN
            30_CD ]_NN ._. The_DT examiner_NN seeks_VBZ corroborating_VBG evidence_NN (_( such_JJ
            as_IN ambulance_NN reports_NNS )_) and_CC carefully_RB screens_VBZ for_IN the_DT
            possibility_NN of_IN onset_NN during_IN sleep_NN ._. The_DT severity_NN of_IN the_DT
            neurologic_JJ deficit_NN is_VBZ assessed_VBN within_IN 48_CD hours_NNS of_IN the_DT
            patient_NN 's_POS enrollment_NN in_IN the_DT study_NN by_IN means_NNS of_IN the_DT
            National_NNP Institutes_NNPS of_IN Health_NNP Stroke_NNP Scale_NNP (_( NIHSS_NNP )_) [_NN 31_CD
            ]_NN administered_VBN by_IN a_DT certified_VBN examiner_NN ._. The_DT first_JJ CT_NNP or_CC
            MR_NNP obtained_VBD is_VBZ used_VBN to_TO measure_VB infarct_NN size_NN by_IN means_NNS of_IN
            standardized_JJ criteria_NNS (_( Appendix_NNP 3_CD -_: see_VB Additional_JJ
            file_NN :_: 3_LS )_) ._.
            Prestroke_NNP functional_JJ status_NN is_VBZ assessed_VBN
            retrospectively_RB by_IN the_DT study_NN coordinator_NN with_IN the_DT
            Oxford_NNP Handicap_NNP Scale_NNP [_NN 32_CD ]_NN ._. Acute_NNP poststroke_NN
            functional_JJ status_NN is_VBZ assessed_VBN with_IN the_DT Oxford_NNP Handicap_NNP
            Scale_NNP [_NN 32_CD ]_NN ,_, Barthel_NNP Index_NNP [_NN 33_CD 34_CD ]_NN ,_, and_CC Glasgow_NNP
            Outcome_NNP Scale_NNP [_NN 35_CD ]_NN within_IN 48_CD hours_NNS of_IN enrollment_NN ._.
            Subtyping_NNP of_IN the_DT index_NN ischemic_JJ stroke_NN is_VBZ done_VBN
            centrally_RB on_IN the_DT basis_NN of_IN the_DT abstracted_JJ medical_JJ record_NN
            by_IN a_DT neurologist_NN adjudicator_NN blinded_JJ to_TO genotype_NN data_NNS
            and_CC personal_JJ indentifiers_NNS ._. Because_IN final_JJ subtype_NN
            diagnosis_NN has_VBZ been_VBN shown_VBN to_TO vary_VB from_IN initial_JJ diagnosis_NN
            in_IN approximately_RB one-third_NN of_IN cases_NNS [_NN 36_CD ]_NN ,_, the_DT
            adjudicator_NN uses_VBZ all_DT available_JJ and_CC relevant_JJ information_NN
            obtained_VBN after_IN completion_NN of_IN the_DT stroke_NN work-up_JJ ._. The_DT
            Trial_NNP of_IN ORG_NNP 10172_CD in_IN Acute_NNP Stroke_NNP Treatment_NNP (_( TOAST_NNP )_) [_NN
            37_CD ]_NN ,_, Oxfordshire_NNP Community_NNP Stroke_NNP Project_NNP (_( OCSP_NNP )_) [_NN 38_CD
            ]_NN ,_, and_CC Baltimore-_NNP Washington_NNP Young_NNP Stroke_NNP Study_NNP (_( BWYSS_NNP )_)
            [_NN 39_CD ]_NN classification_NN systems_NNS are_VBP used_VBN for_IN
            subtyping_VBG ._.
            Additional_JJ file_NN 3_CD
            
            
            Click_NNP here_RB for_IN file_NN
          
          
            Follow-up_JJ of_IN Stroke_NNP Patients_NNPS
            Patients_NNS with_IN stroke_NN are_VBP followed_VBN up_RP by_IN the_DT study_NN
            coordinator_NN at_IN the_DT center_NN from_IN which_WDT they_PRP were_VBD
            recruited_VBN ._. The_DT coordinator_NN reassesses_NNS patients_NNS by_IN using_VBG
            the_DT Oxford_NNP Handicap_NNP Scale_NNP ,_, Barthel_NNP Index_NNP ,_, and_CC Glasgow_NNP
            Outcome_NNP Scale_NNP by_IN telephone_NN interview_NN 90_CD ±_NN 14_CD days_NNS after_IN
            onset_NN of_IN stroke_NN symptoms_NNS ._. Coordinators_NNP preferentially_RB
            interview_NN the_DT patients_NNS themselves_PRP ._. However_RB ,_, if_IN acquired_VBN
            deficits_NNS of_IN speech_NN ,_, language_NN ,_, or_CC cognition_NN prevent_VBP the_DT
            patient_NN from_IN participating_VBG in_IN the_DT telephone_NN outcomes_NNS
            assessment_NN ,_, a_DT surrogate_JJ history_NN is_VBZ taken_VBN from_IN a_DT
            caregiver_NN or_CC live-in_JJ relative_NN ._. Coordinators_NNP will_MD also_RB
            record_VB mortality_NN and_CC history_NN of_IN cause_NN of_IN death_NN from_IN
            collateral_NN sources_NNS ._.
          
          
            Genetic_NNP Data_NNP
            The_DT study_NN coordinator_NN at_IN the_DT local_JJ center_NN obtains_NNS
            two_CD tubes_NNS of_IN peripheral_JJ blood_NN from_IN each_DT patient_NN and_CC
            each_DT control_NN subject_JJ ,_, collected_VBN in_IN a_DT 10_CD -_: mL_NN (_( 8_CD ._. 5_LS -_: mL_NN
            draw_NN )_) acid-citrate-dextrose_JJ solution_NN A_DT (_( ACD_NNP )_) tube_NN ._. The_DT
            blood_NN samples_NNS are_VBP shipped_VBN to_TO a_DT central_JJ DNA_NNP bank_NN by_IN
            overnight_JJ courier_NN and_CC assigned_VBN a_DT unique_JJ repository_NN
            identifier_NN ._. Lymphocytes_NNP are_VBP isolated_VBN ,_, and_CC 0_CD ._. 5_CD mL_NN of_IN
            blood_NN is_VBZ retained_VBN in_IN the_DT original_JJ tube_NN as_IN a_DT quality_NN
            control_NN specimen_NN for_IN identity_NN testing_NN ._. Isolated_NNP
            lymphocytes_NNS are_VBP cryopreserved_JJ using_VBG controlled-rate_JJ
            freezing_NN and_CC stored_VBD at_IN the_DT liquid_JJ phase_NN of_IN
            nitrogen_NN ._.
            The_DT DNA_NNP bank_NN prepares_VBZ high-quality_JJ ,_,
            high-molecular-weight_JJ DNA_NNP from_IN the_DT cell_NN pellet_NN using_VBG a_DT
            modification_NN of_IN the_DT salting-out_JJ procedure_NN of_IN Miller_NNP et_CC
            al_NN ._. [_NN 40_CD ]_NN ._. Quality_NNP control_NN studies_NNS on_IN DNA_NNP consist_VBP of_IN
            estimation_NN of_IN quantity_NN by_IN OD_NNP 260_CD /_NN OD_NNP 280_CD ratio_NN ,_, estimation_NN
            of_IN integrity_NN by_IN gel_NN electrophoresis_NNS and_CC restriction_NN
            digestion_NN ,_, and_CC verification_NN of_IN identity_NN by_IN
            microsatellite_NN analysis_NN and_CC sex_NN determination_NN ._.
            Transformation_NNP of_IN lymphocytes_NNS is_VBZ done_VBN using_VBG
            Epstein-_NNP Barr_NNP virus_NN and_CC phytohemagglutinin_NN ._. Lymphocyte_NNP
            cultures_NNS are_VBP expanded_VBN to_TO produce_VB sufficient_JJ stock_NN for_IN
            10_CD to_TO 12_CD ampules_NNS ._. All_DT cell_NN cultures_NNS are_VBP done_VBN in_IN the_DT
            absence_NN of_IN antibiotics_NNS ._. Cryopreservation_NNP is_VBZ again_RB done_VBN
            by_IN controlled-rate_JJ freezing_NN ._. Samples_NNP are_VBP stored_VBN at_IN the_DT
            liquid_JJ phase_NN of_IN nitrogen_NN ._. In-house_NNP and_CC remote_JJ fail-safe_JJ
            stocks_NNS are_VBP generated_VBN ._. The_DT following_VBG routine_JJ quality_NN
            control_NN studies_NNS for_IN cell_NN culture_NN are_VBP performed_VBN :_:
            recovery_NN of_IN frozen_VBN stock_NN and_CC determination_NN of_IN
            viability_NN ,_, sterility_NN testing_NN for_IN bacterial_JJ and_CC fungal_NN
            contamination_NN ,_, testing_NN for_IN mycoplasma_NN contamination_NN by_IN
            polymerase_NN chain_NN reaction_NN (_( PCR_NNP )_) ,_, and_CC confirmation_NN of_IN
            the_DT identity_NN of_IN the_DT culture_NN by_IN comparing_VBG the_DT DNA_NNP
            fingerprint_NN of_IN the_DT culture_NN with_IN that_DT of_IN the_DT quality_NN
            control_NN specimen_NN ._. If_IN the_DT first_JJ attempt_NN fails_VBZ ,_, a_DT second_JJ
            aliquot_NN of_IN cryopreserved_JJ lymphocytes_NNS can_MD be_VB
            transformed_VBN ._.
            Genotyping_NNP is_VBZ done_VBN at_IN a_DT central_JJ genetics_NNS laboratory_NN ._.
            Currently_RB ,_, the_DT following_VBG sequencing_VBG methods_NNS are_VBP used_VBN ,_,
            but_CC the_DT laboratory_NN will_MD be_VB responsive_JJ to_TO technological_JJ
            advances_NNS in_IN the_DT field_NN ._.
            PCR_NNP is_VBZ carried_VBN out_IN in_IN a_DT 75_CD -_: μL_NN volume_NN on_IN 40_CD -_: ng_NN
            genomic_JJ DNA_NNP by_IN use_NN of_IN plain_JJ primers_NNS under_IN standard_JJ
            conditions_NNS with_IN a_DT 57_CD °_NN to_TO 52_CD °_NN C_NNP (_( 0_CD ._. 5_LS °_NN C_NNP /_NN cycle_NN )_)
            "_'' touch-down_JJ "_'' annealing_VBG temperature_NN ._. To_TO remove_VB excess_JJ
            unincorporated_JJ primers_NNS that_WDT would_MD compete_VB as_IN sequencing_VBG
            primers_NNS in_IN the_DT cycle_NN sequencing_VBG reaction_NN ,_, the_DT amplified_VBN
            product_NN is_VBZ filtered_VBN with_IN MultiScreen_NNP PCR_NNP filters_NNS
            (_( Millipore_NNP )_) and_CC resuspended_JJ in_IN 50_CD μL_NN ._. The_DT sequencing_VBG
            reaction_NN is_VBZ carried_VBN out_IN using_VBG the_DT BigDye_NNP Terminator_NNP
            cycle_NN sequencing_VBG kit_NN (_( Applied_NNP Biosystems_NNP )_) as_IN per_IN the_DT
            manufacturer_NN 's_POS conditions_NNS ._. To_TO remove_VB excess_JJ dye_NN
            terminators_NNS ,_, the_DT sequencing_VBG product_NN is_VBZ purified_JJ by_IN
            ethanol_NN precipitation_NN and_CC resuspended_JJ in_IN 10_CD μL_NN of_IN HiDi_NNP
            formamide_NN ._. The_DT samples_NNS are_VBP then_RB denatured_JJ and_CC
            electrophoresed_JJ on_IN an_DT ABI_NNP 3100_CD capillary_JJ analyzer_NN ._. Data_NNP
            analysis_NN is_VBZ carried_VBN out_IN with_IN a_DT software_NN suite_NN (_( ABI_NNP )_)
            consisting_VBG of_IN Sequencing_NNP Analysis_NNP (_( base_NN calling_VBG )_) ,_,
            Factura_NNP (_( heterozygous_JJ base_NN detection_NN )_) ,_, and_CC Sequence_NNP
            Navigator_NNP (_( sequence_NN comparison_NN )_) ._.
          
          
            Adverse_JJ Events_NNS
            All_DT adverse_JJ events_NNS and_CC serious_JJ adverse_JJ events_NNS will_MD
            be_VB recorded_VBN by_IN the_DT study_NN coordinators_NNS and_CC forwarded_JJ to_TO
            the_DT statistical_JJ center_NN ._. Potential_JJ physical_JJ risks_NNS are_VBP
            minimal_JJ and_CC relate_VBP to_TO the_DT one-time_JJ phlebotomy_NN ._. An_DT
            independent_JJ medical_JJ safety_NN monitor_NN will_MD review_VB summary_NN
            reports_NNS of_IN adverse_JJ events_NNS and_CC serious_JJ adverse_JJ events_NNS
            periodically_RB and_CC will_MD forward_RB assessments_NNS to_TO the_DT study_NN
            Principal_NN Investigator_NNP ._.
          
        
        
          Outcome_NNP Measures_NNS
          The_DT main_JJ end_NN point_NN of_IN the_DT study_NN is_VBZ whether_IN any_DT of_IN the_DT
          polymorphisms_NNS (_( the_DT β-fibrinogen_JJ polymorphisms_NNS C_NNP 148_CD T_NN ,_,
          G_NNP 448_CD A_DT ,_, and_CC G_NNP 455_CD A_DT and_CC the_DT platelet_NN GP_NNP polymorphisms_NNS GPIa_NNP
          C_NNP 807_CD T_NN ,_, GPIbα_NNP HPA-_NNP 2_CD and_CC VNTR_NNP ,_, and_CC GPIIb_NNP /_NN IIIa_NNP P_NN 1_CD A_DT )_) are_VBP
          associated_VBN with_IN ischemic_JJ stroke_NN ._. Thus_RB ,_, patients_NNS with_IN
          stroke_NN will_MD be_VB compared_VBN with_IN controls_NNS as_IN to_TO frequency_NN and_CC
          distribution_NN of_IN these_DT polymorphisms_NNS ._. Other_JJ end_NN points_NNS
          include_VBP potential_JJ associations_NNS among_IN these_DT polymorphisms_NNS
          and_CC individual_JJ subtypes_NNS of_IN ischemic_JJ stroke_NN ,_, ethnic_JJ
          origin_NN ,_, or_CC 90_CD -_: day_NN poststroke_NN functional_JJ outcome_NN and_CC
          mortality_NN ._. Additional_JJ analyses_NNS will_MD include_VB testing_VBG for_IN
          interactions_NNS between_IN inherited_VBN susceptibility_NN (_( genotype_NN )_)
          and_CC environmental_JJ exposures_NNS (_( e_SYM ._. g_SYM ._. ,_, smoking_NN )_) ._.
        
        
          Data_NNP Analyses_NNS
          Several_JJ types_NNS of_IN analyses_NNS will_MD be_VB performed_VBN to_TO assess_VB
          the_DT relationships_NNS between_IN outcome_NN (_( binary_JJ and_CC continuous_JJ )_)
          and_CC risk_NN factors_NNS (_( both_DT genetic_JJ and_CC environmental_JJ )_) ._. The_DT
          statistical_JJ techniques_NNS we_PRP use_VBP to_TO analyze_VB the_DT data_NNS depend_VBP
          on_IN the_DT distribution_NN of_IN the_DT independent_JJ (_( predictor_NN )_) and_CC
          dependent_JJ (_( outcome_NN )_) variables_NNS ._. When_WRB the_DT outcome_NN variables_NNS
          are_VBP categorical_JJ (_( i_NNP ._. e_SYM ._. ,_, stroke_NN [_NN yes_UH /_NN no_DT ]_NN )_) we_PRP will_MD use_VB
          chi-square_JJ tests_NNS and_CC logistic_JJ regression_NN techniques_NNS ;_: when_WRB
          the_DT outcome_NN variables_NNS are_VBP continuous_JJ (_( with_IN or_CC without_IN
          inclusion_NN of_IN collected_VBN longitudinal_NN data_NNS )_) ,_, we_PRP will_MD use_VB
          repeated_VBD measures_NNS analysis_NN of_IN covariance_NN (_( ANCOVA_NNP )_)
          techniques_NNS ._.
          Cases_NNS will_MD be_VB compared_VBN with_IN controls_NNS with_IN respect_NN to_TO
          predictor_NN variables_NNS of_IN interest_NN and_CC with_IN respect_NN to_TO
          genotypes_NNS that_WDT may_MD provide_VB increased_VBN risk_NN for_IN stroke_NN ._.
          Where_WRB needed_VBN ,_, adjustments_NNS for_IN potential_JJ covariates_NNS (_( age_NN ,_,
          sex_NN ,_, hypertension_NN ,_, etc_FW ._. )_) will_MD also_RB be_VB included_VBN in_IN these_DT
          analyses_NNS ._. To_TO perform_VB the_DT above_JJ comparisons_NNS ,_, we_PRP will_MD use_VB
          logistic_JJ regression_NN ,_, a_DT statistical_JJ technique_NN for_IN modeling_VBG
          the_DT relationship_NN of_IN a_DT binary_JJ outcome_NN and_CC a_DT set_NN of_IN
          independent_JJ (_( or_CC predictor_NN )_) variables_NNS [_NN 41_CD ]_NN ._.
          For_IN our_PRP$ case-control_JJ comparisons_NNS ,_, a_DT second_JJ series_NN of_IN
          analyses_NNS relates_VBZ to_TO the_DT distribution_NN of_IN polymorphisms_NNS
          within_IN the_DT selected_VBN candidate_NN genes_NNS in_IN the_DT cases_NNS (_( stroke_NN
          positive_JJ )_) and_CC controls_NNS (_( stroke_NN negative_JJ )_) ._. Each_DT subject_NN
          will_MD be_VB characterized_VBN by_IN the_DT polymorphism_NN (_( or_CC mutation_NN )_)
          found_VBD at_IN each_DT candidate_NN gene_NN ._. Different_JJ analytical_JJ
          strategies_NNS need_VBP to_TO be_VB employed_VBN for_IN the_DT different_JJ
          candidate_NN loci_NN under_IN study_NN ._. For_IN the_DT fibrinogen_NN gene_NN
          cluster_NN ,_, it_PRP is_VBZ proposed_VBN that_IN the_DT genotype_NN be_VB considered_VBN
          as_IN a_DT binary_JJ variable_NN ,_, that_WDT is_VBZ ,_, as_IN a_DT single_JJ nucleotide_NN
          polymorphism_NN (_( SNP_NNP )_) with_IN two_CD possible_JJ alleles_NNS ,_, since_IN the_DT
          outcome_NN of_IN polymorphisms_NNS in_IN genes_NNS of_IN this_DT cluster_NN has_VBZ
          resulted_VBN in_IN apparent_JJ increased_VBN risk_NN for_IN ischemic_JJ heart_NN
          disease_NN through_IN increased_VBN circulating_VBG fibrinogen_NN levels_NNS ._.
          Thus_RB ,_, initial_JJ analyses_NNS using_VBG members_NNS of_IN the_DT fibrinogen_NN
          cluster_NN (_( or_CC with_IN other_JJ candidate_NN genes_NNS such_JJ as_IN GPIbα_NNP )_)
          will_MD focus_VB on_IN each_DT case_NN /_NN control_NN being_VBG classified_VBN by_IN the_DT
          presence_NN of_IN a_DT risk_NN allele_NN (_( yes_UH /_NN no_DT )_) ,_, with_IN comparison_NN of_IN
          SNP_NNP allele_NN frequencies_NNS between_IN groups_NNS
          (_( stroke_NN /_NN control_NN )_) ._.
          For_IN other_JJ candidate_NN genes_NNS (_( GPIbα_NNP ,_, etc_FW ._. )_) ,_, distributions_NNS
          of_IN genotypes_NNS or_CC strata_NN determined_VBN by_IN alleles_NNS or_CC
          haplotypes_NNS can_MD be_VB established_VBN for_IN comparison_NN ._. For_IN
          example_NN ,_, GPIbα_NNP has_VBZ a_DT series_NN of_IN polymorphisms_NNS that_WDT may_MD
          define_VB an_DT allele_NN of_IN interest_NN ._. Extending_NNP SNPs_NNP to_TO
          haplotypes_NNS has_VBZ the_DT advantage_NN of_IN increased_VBN information_NN ,_,
          yet_RB decreased_VBD power_NN in_IN small_JJ samples_NNS due_JJ to_TO the_DT increased_VBN
          number_NN of_IN possible_JJ haplotypes_NNS to_TO be_VB tested_VBN ._. Restriction_NNP
          of_IN haplotypes_NNS by_IN "_'' binning_VBG "_'' may_MD provide_VB some_DT increase_NN in_IN
          power_NN ,_, yet_RB it_PRP assumes_VBZ previous_JJ knowledge_NN of_IN risk_NN
          haplotypes_NNS ._. These_DT few_JJ haplotypes_NNS can_MD be_VB used_VBN to_TO establish_VB
          strata_NN in_IN the_DT analyses_NNS proposed_VBN ._. In_IN separate_JJ analyses_NNS ,_,
          the_DT SNP_NNP /_NN polymorphism_NN status_NN can_MD be_VB considered_VBN to_TO be_VB an_DT
          exposure_NN variable_JJ ._. Thus_RB ,_, risk_NN factor_NN distributions_NNS can_MD be_VB
          compared_VBN between_IN "_'' exposed_VBN "_'' subjects_NNS (_( with_IN a_DT polymorphism_NN
          in_IN a_DT candidate_NN gene_NN )_) and_CC those_DT "_'' not_RB exposed_VBN "_'' (_( without_IN a_DT
          polymorphism_NN )_) ._. For_IN levels_NNS of_IN continuous_JJ risk_NN factors_NNS ,_,
          this_DT analysis_NN will_MD compare_VB means_VBZ by_IN analysis_NN of_IN variance_NN
          methods_NNS ._. For_IN dichotomous_JJ risk_NN factors_NNS ,_, contingency_NN table_NN
          methods_NNS can_MD be_VB used_VBN ._.
          In_IN the_DT case-control_JJ analyses_NNS ,_, each_DT candidate_NN locus_JJ can_MD
          be_VB analyzed_VBN individually_RB as_IN a_DT potential_JJ modifier_NN of_IN
          disease_NN risk_NN (_( stroke_NN )_) and_CC as_IN a_DT determinant_NN of_IN other_JJ
          intermediate_JJ (_( continuous_JJ trait_NN )_) end_NN points_NNS ._. To_TO evaluate_VB
          the_DT relationships_NNS between_IN gene_NN interaction_NN (_( gene-gene_JJ )_)
          and_CC interaction_NN between_IN inherited_VBN susceptibility_NN
          (_( genotype_NN )_) and_CC environmental_JJ exposures_NNS (_( e_SYM ._. g_SYM ._. ,_,
          hypertension_NN or_CC smoking_NN )_) ,_, several_JJ strategies_NNS can_MD be_VB
          employed_VBN ._. One_CD approach_NN is_VBZ stratification_NN by_IN genotype_NN at_IN
          each_DT candidate_NN locus_JJ ,_, with_IN analysis_NN of_IN "_'' case_NN "_'' status_NN with_IN
          the_DT second_JJ genetic_JJ (_( or_CC environmental_JJ )_) exposure_NN ._. For_IN
          dichotomous_JJ exposures_NNS ,_, this_DT reduces_VBZ to_TO a_DT comparison_NN of_IN
          contingency_NN tables_NNS within_IN genotype_NN strata_NN ._.
          A_DT second_JJ approach_NN uses_VBZ logistic_JJ regression_NN ._. Logistic_NNP
          regression_NN can_MD be_VB used_VBN for_IN continuous_JJ risk_NN factors_NNS within_IN
          genotype_NN strata_NN ._. Similarly_RB ,_, multivariate_NN logistic_JJ
          regression_NN can_MD be_VB used_VBN to_TO predict_VB group_NN membership_NN
          (_( stroke_NN vs_NNS ._. control_NN )_) based_VBN on_IN age_NN ,_, sex_NN ,_, environmental_JJ
          risk_NN factors_NNS that_WDT appear_VBP significant_JJ in_IN univariate_NN
          analyses_NNS ,_, and_CC genotype_NN (_( s_VBZ )_) ,_, with_IN first-order_JJ interaction_NN
          terms_NNS of_IN genotype_NN with_IN environment_NN and_CC gene_NN 1_CD with_IN gene_NN
          2_CD ._.
        
        
          Sample_NNP Size_NN and_CC Study_NNP Power_NNP
          We_PRP intend_VBP to_TO enroll_VB a_DT total_NN of_IN 900_CD participants_NNS ,_,
          including_VBG 450_CD patients_NNS with_IN ischemic_JJ stroke_NN (_( cases_NNS )_) and_CC
          450_CD stroke-free_JJ volunteers_NNS (_( controls_NNS )_) ,_, at_IN five_CD academic_JJ
          medical_JJ centers_NNS in_IN the_DT United_NNP States_NNPS over_IN 3_CD years_NNS ._.
          Estimates_NNS of_IN potential_JJ for_IN recruitment_NN were_VBD based_VBN on_IN the_DT
          assumption_NN that_IN the_DT rates_NNS of_IN hospitalized_VBN stroke_NN cases_NNS at_IN
          the_DT five_CD participating_VBG hospitals_NNS will_MD remain_VB at_IN 1999_CD
          levels_NNS throughout_IN the_DT patient_NN recruitment_NN phase_NN of_IN the_DT
          study_NN ._.
          We_PRP anticipate_VBP that_IN the_DT study_NN population_NN will_MD be_VB
          approximately_RB two-thirds_NNS white_NN and_CC one-third_NN African_NNP
          American_NNP ,_, giving_VBG sample_NN sizes_NNS of_IN approximately_RB 300_CD each_DT
          for_IN white_JJ patients_NNS with_IN stroke_NN and_CC control_NN subjects_NNS and_CC
          100_CD each_DT for_IN African_NNP American_JJ patients_NNS with_IN stroke_NN and_CC
          control_NN subjects_NNS ._. Thus_RB ,_, for_IN the_DT above_JJ analyses_NNS ,_, we_PRP are_VBP
          concerned_VBN primarily_RB with_IN dichotomous_JJ outcomes_NNS with_IN fixed_VBN
          sample_NN sizes_NNS (_( 100_CD ,_, 300_CD ,_, or_CC 450_CD stroke_NN cases_NNS and_CC 100_CD ,_, 300_CD ,_,
          or_CC 450_CD controls_NNS )_) ._. Power_NNP for_IN any_DT analyses_NNS involving_VBG
          continuous_JJ measures_NNS can_MD be_VB approximated_JJ using_VBG an_DT
          independent_JJ 
          t_NN test_NN comparison_NN between_IN the_DT
          incident_NN cases_NNS and_CC controls_NNS ._. In_IN the_DT case-control_JJ study_NN ,_,
          the_DT power_NN to_TO address_VB specific_JJ issues_NNS relating_VBG to_TO the_DT
          genetic_JJ associations_NNS is_VBZ dependent_JJ on_IN the_DT sample_NN size_NN
          available_JJ ,_, the_DT frequency_NN of_IN the_DT polymorphisms_NNS (_( in_IN the_DT
          fibrinogen_NN cluster_NN and_CC other_JJ candidate_NN genes_NNS )_) ,_, and_CC the_DT
          size_NN of_IN the_DT effect_NN to_TO be_VB detected_VBN ._.
          The_DT power_NN is_VBZ determined_VBN on_IN the_DT basis_NN of_IN the_DT frequency_NN
          of_IN the_DT SNP_NNP in_IN the_DT control_NN group_NN and_CC the_DT detectable_JJ
          difference_NN in_IN SNP_NNP allele_NN frequency_NN in_IN the_DT control_NN group_NN ._.
          For_IN example_NN ,_, if_IN an_DT SNP_NNP has_VBZ a_DT frequency_NN of_IN 0_CD ._. 40_CD in_IN the_DT
          total_JJ group_NN of_IN controls_NNS (_( 
          n_NN =_SYM 450_CD )_) ,_, we_PRP can_MD detect_VB (_( with_IN 75_CD %_NN
          power_NN )_) a_DT 20_CD %_NN difference_NN in_IN cases_NNS [_NN (_( 0_CD ._. 20_CD )_) (_( 0_CD ._. 40_CD )_) =_SYM 0_CD ._. 08_CD ]_NN or_CC
          frequencies_NNS greater_JJR than_IN 0_CD ._. 48_CD or_CC less_JJR than_IN 0_CD ._. 32_CD in_IN cases_NNS ._.
          This_DT is_VBZ obviously_RB a_DT small_JJ difference_NN (_( or_CC a_DT relatively_RB
          weak_JJ genetic_JJ relative_JJ risk_NN )_) ._. Using_VBG this_DT same_JJ example_NN ,_, we_PRP
          would_MD have_VB 46_CD %_NN power_NN in_IN whites_NNS and_CC 22_CD %_NN power_NN in_IN African_NNP
          Americans_NNPS ._. For_IN the_DT African_NNP American_JJ group_NN ,_, we_PRP generally_RB
          have_VBP power_NN for_IN relatively_RB high-frequency_JJ polymorphisms_NNS in_IN
          controls_NNS (_( approximately_RB 45_CD %_NN -_: 50_CD %_NN )_) and_CC detectable_JJ
          differences_NNS of_IN 40_CD %_NN in_IN cases_NNS (_( 0_CD ._. 20_CD difference_NN )_) ._. Thus_RB ,_, we_PRP
          could_MD detect_VB an_DT SNP_NNP allele_NN frequency_NN of_IN 0_CD ._. 70_CD in_IN cases_NNS and_CC
          0_CD ._. 45_CD in_IN controls_NNS with_IN 80_CD %_NN power_NN ._.
          In_IN general_JJ ,_, the_DT power_NN to_TO detect_VB gene-environment_JJ
          interaction_NN effects_NNS is_VBZ less_JJR than_IN that_DT for_IN main_JJ effects_NNS
          and_CC is_VBZ dependent_JJ on_IN the_DT type_NN of_IN interaction_NN ._. For_IN example_NN ,_,
          using_VBG methods_NNS discussed_VBN by_IN Goodman_NNP [_NN 42_CD ]_NN ,_, the_DT power_NN to_TO
          detect_VB interactions_NNS for_IN multiple_JJ scenarios_NNS is_VBZ possible_JJ ._.
          For_IN these_DT scenarios_NNS ,_, 2_CD ×_NN 2_CD tables_NNS can_MD be_VB used_VBN to_TO describe_VB
          the_DT overall_JJ main_JJ effects_NNS of_IN genetic_JJ and_CC environmental_JJ
          risks_NNS (_( i_NNP ._. e_SYM ._. ,_, both_DT the_DT genetic_JJ and_CC the_DT environmental_JJ risk_NN
          factors_NNS display_VBP a_DT main_JJ effect_NN size_NN [_NN odds_NNS ratio_NN ]_NN of_IN about_IN
          4_LS )_) ._.
          For_IN large_JJ interactions_NNS we_PRP have_VBP >_NN 99_CD %_NN statistical_JJ
          power_NN ._. Only_RB in_IN the_DT smallest_JJS subgroup_NN would_MD power_VB be_VB
          appreciably_RB affected_VBN ._. For_IN example_NN ,_, for_IN the_DT African_NNP
          American_JJ group_NN (_( 100_CD cases_NNS and_CC 100_CD controls_NNS )_) ,_, with_IN the_DT
          same_JJ distribution_NN of_IN individuals_NNS as_IN above_IN ,_, the_DT power_NN to_TO
          detect_VB the_DT large_JJ interactions_NNS (_( OR_NNP of_IN 0_CD ._. 33_CD in_IN controls_NNS ,_, OR_NNP
          of_IN 5_CD ._. 33_CD in_IN cases_NNS )_) would_MD still_RB be_VB ~_NN 99_CD %_NN ,_, while_IN the_DT power_NN to_TO
          detect_VB the_DT modest_JJ interaction_NN (_( OR_NNP of_IN 0_CD ._. 80_CD in_IN controls_NNS ,_, OR_NNP
          of_IN 1_CD ._. 50_CD in_IN cases_NNS )_) would_MD be_VB reduced_VBN to_TO 13_CD %_NN ._.
        
      
      
        Ethical_NNP Considerations_NNP
        Local_JJ institutional_JJ review_NN boards_NNS (_( IRBs_NNP )_) governing_VBG each_DT
        clinical_JJ center_NN have_VBP approved_VBN the_DT study_NN protocol_NN ._. Written_VBN
        informed_VBN consent_NN is_VBZ obtained_VBN for_IN every_DT study_NN subject_JJ ._. To_TO
        the_DT extent_NN permitted_VBN by_IN local_JJ IRBs_NNP ,_, surrogate_JJ consent_NN is_VBZ
        permitted_VBN for_IN patients_NNS rendered_VBD incompetent_JJ by_IN stroke_NN to_TO
        avoid_VB biasing_VBG the_DT study_NN toward_IN discovery_NN of_IN risk_NN factors_NNS
        for_IN mild_JJ or_CC moderate_JJ stroke_NN but_CC not_RB severe_JJ stroke_NN ._.
        Genetic_JJ information_NN has_VBZ the_DT potential_NN to_TO adversely_RB
        affect_VB insurability_NN and_CC employability_NN [_NN 43_CD 44_CD ]_NN ._. An_DT
        individual_NN 's_POS genetic_JJ information_NN could_MD also_RB lead_VB to_TO
        stigmatization_NN within_IN a_DT family_NN and_CC a_DT community_NN [_NN 45_CD ]_NN ._.
        Because_IN of_IN the_DT highly_RB sensitive_JJ nature_NN of_IN genetic_JJ
        information_NN ,_, we_PRP have_VBP developed_VBN the_DT following_VBG plan_NN to_TO
        prevent_VB intentional_JJ or_CC unintentional_NN misuse_NN of_IN genetic_JJ
        data_NNS ,_, which_WDT is_VBZ in_IN keeping_VBG with_IN the_DT Privacy_NNP Workshop_NNP
        Planning_NNP Subcommittee_NNP Guidelines_NNS of_IN the_DT National_NNP Action_NNP
        Plan_NNP on_IN Breast_NNP Cancer_NNP [_NN 46_CD ]_NN ._.
        Every_DT ISGS_NNP investigator_NN who_WP obtains_NNS or_CC has_VBZ access_NN to_TO
        genotypic_JJ data_NNS is_VBZ blinded_JJ to_TO individual_JJ personal_JJ
        identifiers_NNS ,_, and_CC every_DT investigator_NN who_WP obtains_NNS or_CC has_VBZ
        access_NN to_TO individual_JJ personal_JJ identifiers_NNS is_VBZ blinded_JJ to_TO
        genotypic_JJ data_NNS ._. Personal_JJ identifiers_NNS are_VBP defined_VBN as_IN
        individual_JJ names_NNS ,_, addresses_NNS ,_, phone_NN numbers_NNS ,_, fax_NN numbers_NNS ,_,
        and_CC e-mail_JJ addresses_NNS ._. Personal_JJ identifiers_NNS and_CC linkage_NN
        codes_NNS are_VBP kept_VBN only_RB at_IN the_DT clinical_JJ center_NN where_WRB the_DT study_NN
        subject_NN was_VBD enrolled_VBN and_CC will_MD not_RB be_VB recorded_VBN on_IN case_NN
        report_NN forms_NNS or_CC stored_VBD in_IN the_DT study_NN electronic_JJ database_NN ._.
        Experimental_NNP research_NN data_NNS are_VBP not_RB placed_VBN in_IN a_DT
        participant_NN 's_POS medical_JJ record_NN ._. There_EX have_VBP been_VBN various_JJ
        opinions_NNS regarding_VBG whether_IN family_NN members_NNS should_MD be_VB
        considered_VBN human_JJ subjects_NNS in_IN pedigree_NN research_NN and_CC when_WRB it_PRP
        is_VBZ permissible_JJ to_TO waive_VB consent_NN [_NN 28_CD 47_CD 48_CD 49_CD ]_NN ._. In_IN ISGS_NNP ,_,
        no_DT personal_JJ identifiers_NNS are_VBP collected_VBN on_IN family_NN
        members_NNS ._.
        The_DT protocol_NN of_IN ISGS_NNP calls_VBZ for_IN centrally_RB banking_VBG DNA_NNP and_CC
        creating_VBG immortalized_JJ cell_NN lines_NNS ._. Unlike_IN the_DT situation_NN in_IN
        clinical_JJ trial_NN research_NN ,_, no_DT broad_JJ consensus_NN on_IN research_NN
        ethics_NNS exists_VBZ among_IN investigators_NNS and_CC eligible_JJ participants_NNS
        in_IN the_DT field_NN of_IN human_JJ molecular_JJ genetics_NNS research_NN ._. Of_IN
        recent_JJ contention_NN are_VBP procedures_NNS for_IN ensuring_VBG ethical_JJ
        future_JJ use_NN of_IN stored_VBD genetic_JJ material_NN [_NN 50_CD 51_CD ]_NN ._. The_DT
        potential_NN for_IN future_JJ use_NN of_IN DNA_NNP should_MD be_VB anticipated_VBN ,_, even_RB
        if_IN the_DT specific_JJ studies_NNS cannot_NN be_VB known_VBN ._. A_DT future-use_JJ
        agreement_NN should_MD respect_VB genetic_JJ privacy_NN rights_NNS and_CC
        autonomy_NN of_IN human_JJ subjects_NNS while_IN encouraging_VBG scientific_JJ
        inquiry_NN ._. Establishing_VBG a_DT transparent_JJ and_CC ethically_RB sound_VB
        future-use_JJ agreement_NN for_IN research_NN in_IN this_DT field_NN facilitates_NNS
        multicenter_NN collaborations_NNS and_CC future_JJ research_NN ._. After_IN
        reviewing_VBG available_JJ policy_NN statements_NNS from_IN genetics_NNS
        societies_NNS and_CC governmental_JJ agencies_NNS ,_, we_PRP developed_VBD the_DT
        following_VBG list_NN of_IN key_JJ principles_NNS ,_, which_WDT are_VBP incorporated_VBN
        into_IN a_DT future-use_JJ agreement_NN governing_VBG DNA_NNP banked_JJ for_IN this_DT
        study_NN :_: 1_LS )_) Subjects_NNP must_MD provide_VB informed_VBN consent_NN to_TO the_DT
        original_JJ study_NN at_IN the_DT time_NN of_IN DNA_NNP collection_NN ._. 2_LS )_) The_DT
        original_JJ study_NN must_MD have_VB a_DT rigorous_JJ procedure_NN in_IN place_NN to_TO
        protect_VB privacy_NN of_IN study_NN subjects_NNS prior_RB to_TO DNA_NNP collection_NN ._.
        3_LS )_) Patients_NNPS should_MD have_VB the_DT option_NN to_TO consent_VB to_TO ,_, or_CC
        refrain_VB from_IN ,_, participation_NN in_IN future_JJ research_NN at_IN the_DT time_NN
        of_IN the_DT initial_JJ consent_NN process_NN ._. 4_LS )_) Levels_NNP of_IN consent_NN must_MD
        be_VB clear_JJ ,_, explicit_JJ ,_, and_CC exclusive_JJ (_( e_SYM ._. g_SYM ._. ,_, original_JJ study_NN
        only_RB ,_, any_DT stroke_NN study_NN ,_, any_DT study_NN )_) ._. 5_LS )_) Applications_NNS for_IN
        future_JJ use_NN need_VBP to_TO be_VB reviewed_VBN formally_RB ._. 6_CD )_) Study_NNP
        investigators_NNS can_MD release_VB DNA_NNP for_IN future_JJ use_NN only_RB after_IN
        determining_VBG whether_IN the_DT new_JJ study_NN conforms_VBZ to_TO the_DT type_NN of_IN
        research_NN permitted_VBN by_IN the_DT donor_NN ._. 7_CD )_) All_DT specimens_NNS are_VBP
        stripped_VBN of_IN direct_JJ personal_JJ identifiers_NNS before_IN future_JJ use_NN ._.
        8_CD )_) Anonymous_NNP data_NNS sets_NNS with_IN genetic_JJ information_NN from_IN
        different_JJ studies_NNS may_MD be_VB merged_VBN for_IN hypothesis-generating_JJ
        analyses_NNS ._. We_PRP believe_VBP that_IN this_DT carefully_RB developed_VBN ,_,
        publicly_RB scrutinized_VBN future-use_JJ agreement_NN is_VBZ a_DT unique_JJ
        strength_NN of_IN this_DT study_NN and_CC hope_VBP that_IN this_DT proactive_JJ
        approach_NN will_MD avoid_VB some_DT of_IN the_DT rancorous_JJ misunderstandings_NNS
        that_IN other_JJ investigative_JJ groups_NNS have_VBP encountered_VBN in_IN genetic_JJ
        and_CC pedigree_NN research_NN [_NN 51_CD ]_NN ._.
      
      
        Discussion_NNP
        Defining_VBG the_DT molecular_JJ basis_NN for_IN the_DT inherited_VBN component_NN
        to_TO ischemic_JJ stroke_NN risk_NN will_MD require_VB converging_VBG lines_NNS of_IN
        evidence_NN from_IN various_JJ methodologies_NNS ,_, including_VBG genomewide_NN
        screens_NNS [_NN 24_CD ]_NN and_CC candidate_NN gene_NN association_NN studies_NNS ._.
        Collection_NNP of_IN DNA_NNP samples_NNS from_IN a_DT large_JJ cohort_NN of_IN ischemic_JJ
        stroke_NN pedigrees_NNS is_VBZ logistically_RB challenging_VBG ._. Collection_NNP of_IN
        DNA_NNP samples_NNS from_IN patients_NNS with_IN stroke_NN and_CC unrelated_JJ
        stroke-free_JJ controls_NNS is_VBZ more_RBR feasible_JJ ._.
        Some_DT stroke_NN genetics_NNS research_NN has_VBZ been_VBN done_VBN in_IN the_DT
        context_NN of_IN epidemiological_JJ studies_NNS ;_: for_IN example_NN ,_, a_DT study_NN by_IN
        Ridker_NNP and_CC colleagues_NNS [_NN 15_CD ]_NN tested_VBN for_IN an_DT association_NN
        between_IN factor_NN V_NNP Leiden_NNP and_CC stroke_NN ._. One_CD limitation_NN of_IN this_DT
        approach_NN is_VBZ that_IN there_EX may_MD be_VB relatively_RB few_JJ stroke_NN end_NN
        points_NNS in_IN an_DT epidemiological_JJ study_NN ,_, particularly_RB because_IN
        stroke_NN ,_, myocardial_NN infarction_NN ,_, and_CC vascular_NN death_NN are_VBP often_RB
        combined_VBN as_IN the_DT primary_JJ end_NN point_NN ._. Furthermore_RB ,_, for_IN various_JJ
        reasons_NNS ,_, epidemiological_JJ studies_NNS may_MD include_VB a_DT selected_VBN
        population_NN ,_, for_IN example_NN ,_, only_RB one_CD sex_NN or_CC a_DT limited_JJ
        socioeconomic_JJ stratum_NN ._. The_DT use_NN of_IN such_JJ highly_RB selected_VBN
        samples_NNS may_MD compromise_VB the_DT ability_NN to_TO generalize_VB the_DT
        findings_NNS of_IN a_DT genetic_JJ association_NN study_NN ._.
        Genetic_JJ association_NN can_MD be_VB studied_VBN within_IN the_DT context_NN of_IN
        a_DT clinical_JJ trial_NN of_IN an_DT intervention_NN for_IN primary_JJ prevention_NN ._.
        In_IN a_DT prevention_NN study_NN ,_, DNA_NNP would_MD be_VB available_JJ both_DT from_IN
        patients_NNS with_IN stroke_NN and_CC from_IN stroke-free_JJ controls_NNS ,_, but_CC the_DT
        intervention_NN may_MD alter_VB the_DT outcome_NN (_( stroke_NN )_) sufficiently_RB to_TO
        confound_NN interpretation_NN of_IN the_DT results_NNS of_IN a_DT genetic_JJ
        association_NN study_NN ._.
        A_DT genetic_JJ study_NN in_IN the_DT context_NN of_IN a_DT randomized_JJ trial_NN of_IN
        treatment_NN of_IN stroke_NN patients_NNS is_VBZ a_DT robust_JJ study_NN design_NN when_WRB
        the_DT goal_NN is_VBZ to_TO discover_VB genetic_JJ determinants_NNS of_IN stroke_NN
        outcome_NN or_CC response_NN to_TO therapy_NN (_( pharmacogenomics_NNS )_) ._. However_RB ,_,
        such_JJ a_DT study_NN design_NN may_MD not_RB achieve_VB the_DT goal_NN of_IN discovering_VBG
        genetic_JJ risk_NN factors_NNS for_IN stroke_NN because_IN no_DT genetic_JJ material_NN
        from_IN stroke-free_JJ controls_NNS outside_IN of_IN the_DT study_NN would_MD be_VB
        available_JJ ._. Furthermore_RB ,_, highly_RB restrictive_JJ criteria_NNS for_IN
        eligibility_NN into_IN a_DT clinical_JJ trial_NN can_MD drastically_RB limit_VB the_DT
        representativeness_NNS of_IN a_DT study_NN population_NN ._. For_IN example_NN ,_, in_IN
        one_CD study_NN of_IN intra-arterial_JJ thrombolysis_NNS for_IN treatment_NN of_IN
        acute_JJ ischemic_JJ stroke_NN ,_, 12_CD ,_, 323_CD patients_NNS with_IN stroke_NN were_VBD
        screened_VBD ,_, and_CC only_RB 180_CD patients_NNS were_VBD selected_VBN [_NN 4_CD ]_NN ._. Other_JJ
        stroke_NN studies_NNS include_VBP only_RB patients_NNS with_IN nondisabling_VBG
        strokes_NNS [_NN 52_CD ]_NN ,_, or_CC include_VBP only_RB patients_NNS with_IN moderate_JJ to_TO
        severe_JJ strokes_NNS [_NN 4_CD ]_NN ._. Because_IN ISGS_NNP is_VBZ a_DT dedicated_VBN stroke_NN
        genetic_JJ association_NN study_NN ,_, it_PRP has_VBZ broad_JJ eligibility_NN
        criteria_NNS relative_JJ to_TO clinical_JJ trials_NNS of_IN drugs_NNS or_CC devices_NNS ._.
        We_PRP expect_VBP this_DT to_TO enhance_VB the_DT external_JJ validity_NN of_IN the_DT
        results_NNS of_IN the_DT study_NN ._.
        Additionally_RB ,_, we_PRP have_VBP given_VBN careful_JJ attention_NN to_TO
        appropriate_JJ selection_NN of_IN controls_NNS [_NN 27_CD ]_NN ._. The_DT controls_NNS are_VBP
        concurrently_RB enrolled_VBN at_IN the_DT same_JJ centers_NNS as_IN are_VBP the_DT
        patients_NNS ,_, and_CC controls_NNS are_VBP also_RB screened_VBD for_IN a_DT medical_JJ
        history_NN of_IN stroke_NN or_CC transient_JJ ischemic_JJ attack_NN and_CC for_IN the_DT
        presence_NN of_IN symptoms_NNS of_IN stroke_NN or_CC transient_JJ ischemic_JJ attack_NN
        which_WDT may_MD have_VB occurred_VBN in_IN the_DT absence_NN of_IN a_DT corresponding_JJ
        medical_JJ history_NN ._.
        A_DT unique_JJ strength_NN of_IN ISGS_NNP is_VBZ that_IN the_DT protocol_NN was_VBD
        specifically_RB developed_VBN to_TO permit_VB valid_JJ future_JJ pooled_VBN
        analyses_NNS with_IN the_DT ongoing_JJ affected_VBN sibling_VBG pair_NN linkage_NN
        study_NN SWISS_NNP [_NN 24_CD 53_CD ]_NN ,_, which_WDT uses_VBZ genome-wide_JJ screening_NN
        within_IN a_DT cohort_NN of_IN pedigrees_NNS to_TO identify_VB chromosomal_NN
        regions_NNS -_: rather_RB than_IN specific_JJ polymorphisms_NNS -_: that_WDT are_VBP
        linked_VBN to_TO stroke_NN ._. Conducting_NNP a_DT candidate_NN gene_NN association_NN
        study_NN in_IN cases_NNS and_CC controls_NNS has_VBZ advantages_NNS compared_VBN with_IN
        the_DT genome-wide_JJ linkage_NN approach_NN in_IN siblings_NNS ._. Isolated_NNP
        cases_NNS are_VBP more_RBR likely_JJ to_TO be_VB available_JJ than_IN sibling_VBG pairs_NNS ,_,
        increasing_VBG the_DT potential_NN for_IN statistical_JJ power_NN ._.
        Furthermore_RB ,_, determination_NN of_IN phenotype_NN is_VBZ often_RB
        retrospective_NN in_IN genome-wide_JJ linkage_NN studies_NNS because_IN it_PRP is_VBZ
        rarely_RB possible_JJ to_TO enroll_VB all_DT affected_VBN members_NNS of_IN a_DT
        pedigree_NN shortly_RB after_IN onset_NN of_IN stroke_NN ._. In_IN contrast_NN ,_, the_DT
        case-control_JJ approach_NN allows_VBZ prospective_JJ phenotyping_VBG of_IN all_DT
        subjects_NNS at_IN the_DT time_NN of_IN onset_NN of_IN stroke_NN ,_, which_WDT may_MD be_VB more_RBR
        reliable_JJ than_IN retrospective_NN phenotyping_VBG ._. This_DT is_VBZ an_DT
        advantage_NN because_IN ischemic_JJ stroke_NN has_VBZ a_DT heterogeneous_JJ
        phenotype_NN ,_, and_CC distinctions_NNS between_IN specific_JJ clinical_JJ
        subtypes_NNS of_IN ischemic_JJ stroke_NN may_MD be_VB relevant_JJ [_NN 54_CD 55_CD ]_NN ._. To_TO
        address_VB the_DT heterogeneity_NN of_IN the_DT ischemic_JJ stroke_NN phenotype_NN ,_,
        ischemic_JJ stroke_NN is_VBZ subtyped_JJ by_IN a_DT genotype-blinded_JJ
        adjudicator_NN in_IN both_DT ISGS_NNP and_CC SWISS_NNP ._.
        ISGS_NNP and_CC SWISS_NNP also_RB use_NN the_DT same_JJ definitions_NNS for_IN
        ischemic_JJ stroke_NN and_CC comorbidity_NN and_CC the_DT same_JJ criteria_NNS for_IN
        classifying_VBG stroke_NN mechanism_NN ._. Both_DT studies_NNS use_VBP the_DT same_JJ key_JJ
        exclusion_NN criteria_NNS ;_: for_IN example_NN ,_, both_DT studies_NNS exclude_VBP
        iatrogenic_JJ and_CC vasospastic_JJ ischemic_JJ stroke_NN patients_NNS and_CC
        exclude_VB the_DT same_JJ mendelian_NN and_CC mitochondrial_NN disorders_NNS ._. In_IN
        addition_NN ,_, the_DT stroke-free_JJ status_NN of_IN controls_NNS in_IN ISGS_NNP and_CC of_IN
        discordant_JJ siblings_NNS in_IN SWISS_NNP is_VBZ verified_VBN using_VBG the_DT same_JJ
        structured_VBN interview_NN instrument_NN (_( i_NNP ._. e_SYM ._. ,_, the_DT QVSS_NNP [_NN 25_CD ]_NN )_) ._.
        We_PRP anticipate_VBP that_IN the_DT two_CD studies_NNS will_MD complement_VB each_DT
        other_JJ in_IN contributing_VBG to_TO the_DT broad_JJ ,_, long-term_JJ objective_NN of_IN
        defining_VBG the_DT molecular_JJ basis_NN for_IN inherited_VBN ischemic_JJ stroke_NN
        risk_NN ._.
      
      
        List_NN of_IN abbreviations_NNS
        BWYSS_NNP ,_, Baltimore-_NNP Washington_NNP Young_NNP Stroke_NNP Study_NNP
        CT_NNP ,_, Computed_NNP tomography_NN
        GP_NNP ,_, Glycoprotein_NNP
        ISGS_NNP ,_, Ischemic_NNP Stroke_NNP Genetics_NNP Study_NNP
        MR_NNP ,_, Magnetic_JJ resonance_NN imaging_NN
        NIHSS_NNP ,_, National_NNP Institutes_NNPS of_IN Health_NNP Stroke_NNP Scale_NNP
        OCSP_NNP ,_, Oxfordshire_NNP Community_NNP Stroke_NNP Project_NNP
        OR_NNP ,_, Odds_NNS ratio_NN
        PCR_NNP ,_, Polymerase_NNP chain_NN reaction_NN
        QVSS_NNP ,_, Questionnaire_NNP for_IN Verifying_NNP Stroke_NNP Status_NNP
        SWISS_NNP ,_, Siblings_NNP With_IN Ischemic_NNP Stroke_NNP Study_NNP
        TOAST_NNP ,_, Trial_NNP of_IN ORG_NNP 10172_CD in_IN Acute_NNP Stroke_NNP Treatment_NNP
        vWF_NN ,_, von_NNP Willebrand_NNP factor_NN
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        Dr_NNP ._. Meschia_NNP is_VBZ the_DT principal_JJ investigator_NN in_IN ISGS_NNP ,_,
        developing_VBG and_CC writing_VBG the_DT protocol_NN from_IN its_PRP$ inception_NN to_TO
        the_DT final_JJ version_NN ._. Drs_NNP ._. Brott_NNP ,_, Brown_NNP ,_, Frankel_NNP ,_, Merino_NNP ,_,
        Silliman_NNP and_CC Worrall_NNP are_VBP site_NN investigators_NNS who_WP contributed_VBD
        to_TO developing_VBG and_CC writing_VBG the_DT final_JJ protocol_NN ._. Dr_NNP ._. Hardy_NNP and_CC
        Mr_NNP ._. Crook_NNP contributed_VBD to_TO writing_VBG the_DT portions_NNS of_IN the_DT
        manuscript_NN that_WDT refer_VBP specifically_RB to_TO DNA_NNP sequencing_VBG and_CC
        analysis_NN ._. Dr_NNP ._. Rich_NNP contributed_VBD to_TO writing_VBG the_DT portion_NN of_IN
        the_DT manuscript_NN that_WDT refers_VBZ to_TO the_DT statistical_JJ analytical_JJ
        plan_NN ._.
      
      
        Acknowledgements_NNP
        This_DT study_NN is_VBZ supported_VBN by_IN NIH_NNP NINDS_NNP RO_NNP 1_CD NS-_NNP 42733_CD
        (_( J_NNP ._. F_NN ._. M_NNP ._. )_)
      
    
  
